What “stem cell therapy” can mean
“Stem cell therapy” is an umbrella term, not a single standard treatment. It may refer to established hematopoietic stem-cell transplantation, investigational cell products, mesenchymal stromal cell preparations, organ-specific progenitor cells or commercial offers that use the same language without the same evidence or regulatory status.
For an international patient, the useful question is not simply whether China “has stem cell therapy.” The useful questions are: which exact product or procedure is being proposed, for which condition, under which legal and clinical pathway, at which institution, and with what eligibility and follow-up requirements?
Cell source, ownership and product identity
Cell source affects collection, manufacturing, immune compatibility, risk and evidence. Autologous cells come from the patient; allogeneic cells come from a donor. Products may originate from bone marrow, adipose tissue, umbilical cord, blood or organ-specific tissue. These sources are not interchangeable.
Autologous
Collected from the patient. The pathway may involve sampling, processing, quality testing and later administration.
Allogeneic
Derived from a donor. Donor screening, manufacturing consistency, immunologic considerations and storage matter.
A credible provider should identify the product, cell source, manufacturing site, route of administration and intended indication. Vague descriptions such as “premium young cells” are not enough.
Clinical application, drug trial and research are different
China’s regulatory framework distinguishes clinical research from clinical translation and from product pathways governed by drug or medical-device regulation. A registered study does not automatically mean a treatment can be sold as routine care, and a hospital research direction does not mean patients can currently access it.
Important distinction
Clinical-trial participation is controlled by a protocol, ethics oversight and informed consent. It should not be packaged as a guaranteed paid treatment. Commercial quotations should clearly identify what is medical care, what is research-related and what is coordination.
Evidence and realistic expectations
Evidence should be assessed for the specific cell product, condition, disease stage, route and outcome — not borrowed from unrelated studies. Early safety data, a small uncontrolled case series and a randomised clinical trial provide different levels of information.
Patients should ask what improvement is being measured, how long follow-up lasted, what adverse events occurred and whether the evidence applies to people with similar disease severity. A promise to “reverse aging,” “cure diabetes” or treat many unrelated diseases with one infusion is a major warning sign.
Questions to ask before accepting an offer
- What is the exact name and source of the cell product?
- Which hospital and department will be medically responsible?
- What is the regulatory or clinical route for this specific indication?
- What records are needed to determine eligibility?
- What benefits are supported by condition-specific evidence?
- What are the known and uncertain risks?
- Who manages complications and follow-up?
- Which fees are charged by the hospital, and which are non-medical coordination fees?
How Regenerative Medicine China helps
We do not select a therapy from a menu or promise that a patient qualifies. We first clarify the diagnosis and treatment goal, review the offer or pathway, identify missing records and coordinate formal assessment by an appropriate medical institution when a credible route exists.